Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer 

Abstract

The application of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) has significantly improved the survival of patients with EGFR-mutant non-small cell lung cancer (NSCLC). However, there are still a portion of patients with poor efficacy and prognosis. Therefore, it is urgently needed to find effective emerging prognostic markers. In the past few years, tumor mutational burden (TMB) was mainly used to screen patients who benefitted from immunotherapy and predict the efficacy. Recently, there are also corresponding exploratory studies on EGFR-mutant NSCLC. In this review, we summarized the challenges of TMB test and latest clinical research in EGFR-mutant advanced NSCLC.

Keywords

• non-small cell lung cancer| tumor mutational burden|epidermal growth factor receptor|next-generation sequencing|comprehensive genomic profiling| prognosis